Mehmet Ramazan Şekeroğlu

Mehmet Ramazan Şekeroğlu

Auto-generated profile, based on publicly available information

Mehmet Ramazan Şekeroğlu

SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, TEMEL TIP BİLİMLERİ BÖLÜMÜ

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in Clinical Biochemistry
Verified
Journal Article
Closed access
MŞMehmet Ramazan Şekeroğlu
Mehmet Ramazan Şekeroğlu
HSHavva Sahin
Havva Sahin
HDHaluk Dülger
Haluk Dülger
EAEkrem Algün
Ekrem Algün

30 April 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
AGAhmed Bilal Genc
Ahmed Bilal Genc
SYSelcuk Yaylaci
Selcuk Yaylaci
HDHamad Dheir
Hamad Dheir
AGAHMED CIHAD GENC
AHMED CIHAD GENC
KIKubilay Issever
Kubilay Issever
EGErtuğrul GÜÇLÜ
Ertuğrul GÜÇLÜ
The purpose of this study is to evaluate serum Pentraxin-3 (PTX-3) levels in Sars-CoV-2 virus infection (COVID-19) patients and to investigate whether PTX-3 predicts the disease prognosis. This study was conducted on 88 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia between April 15 2020 and August 15 2020. The patients were divided into two groups as survived patients and non-survived patients. Both groups were compared according to demographic features, comorbid conditions and measurement of the PTX-3 and other laboratory parameters of the patients. Of 88 patients with COVID-19, 59 (67%) were discharged with complete cure and 29 (33%) resulted in death. 46 (52.3%) of the patients were men. PTX-3 median value [IQR] was 3.66 ng/mL (0.9-27.9) in all patients, 3.3 ng/mL (0.9-27.9) in survivors and 3.91 ng/mL (1.9-23.2) in non-survivors which was significantly higher (p= 0.045). As a receiver operating characteristic curve analysis the cut-off value of PTX-3 for predicting mortality in patients was 3.73 with 65% sensitivity and 65% specificity (AUC: 0.646, 95% CI: 0.525-0.767, P= 0.045). Also, we found significant cut-off values with respect to D-Dimer, D-Dimer/ PTX-3, high-sensitivity troponin, high-sensitivity troponin/ PTX-3, lymphocyte, PTX-3/ lymphocyte, procalcitonin, procalcitonin/ PTX-3, CRP, and CRP/ PTX-3 (P<0.05). In this study, as far as we know, for the first time, we have shown PTX-3 as the new mortality biomarker for COVID-19 disease.

1 March 2012 in Clinical Biochemistry
Verified
Journal Article
Closed access
MŞMehmet Ramazan Şekeroğlu
Mehmet Ramazan Şekeroğlu
ZHZübeyr Huyut
Zübeyr Huyut
AHAydın Him
Aydın Him

24 February 2011 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
ŞDŞerafettin Demirci
Şerafettin Demirci
MŞMehmet Ramazan Şekeroğlu
Mehmet Ramazan Şekeroğlu
TNTevfik Noyan
Tevfik Noyan
RKRuşen Köçeroğlu
Ruşen Köçeroğlu
YSYasemin Usul Soyoral
Yasemin Usul Soyoral
REReha Erkoç
Reha Erkoç

1 June 2002 in Clinical Biochemistry
Verified
Journal Article
Closed access
MŞMehmet Ramazan Şekeroğlu
Mehmet Ramazan Şekeroğlu
SASabahattin Aydın
Sabahattin Aydın
HDHaluk Dülger
Haluk Dülger
YYYüksel Yılmaz
Yüksel Yılmaz
HBHaşmet Bayraklı
Haşmet Bayraklı
TNTevfik Noyan
Tevfik Noyan

26 July 2021 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
PDF file
ZOZeynep Ozman
Zeynep Ozman
GEGamze Guney Eskiler
Gamze Guney Eskiler
MSMehmet R. Sekeroglu
Mehmet R. Sekeroglu